🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Found 20 matching trials

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

PHASE2

The objective of this Phase II study is to assess the potential of ascimini...

Status

Recruiting

Location

Novartis Investigative Site

Start Date

2025-02-18

Trial ID

NCT06514534

Treatments Being Tested

ABL001/Asciminib

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

PHASE4

The Drugs Controller General of India (DCGI) has granted approval for Ascim...

Status

Completed

Location

Novartis Investigative Site

Start Date

2024-11-28

Trial ID

NCT06427811

Treatments Being Tested

Asciminib

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

PHASE2

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone...

Status

Active Not Recruiting

Location

H. Lee Moffitt Cancer Center and Research Institute

Start Date

2019-11-19

Trial ID

NCT03610971

Treatments Being Tested

Ruxolitinib BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

PHASE3

This phase III trial compares the effect of usual treatment of chemotherapy...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2021-01-25

Trial ID

NCT04530565

Treatments Being Tested

Biospecimen Collection Blinatumomab Bone Marrow Aspiration and Biopsy Cyclophosphamide Cytarabine Dasatinib Dexamethasone Doxorubicin Hydrochloride Echocardiography Test Electrocardiography Lumbar Puncture Mesna Methotrexate Multigated Acquisition Scan Ponatinib Hydrochloride Prednisone Vincristine Sulfate

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

N/A

This non-interventional, prospective study will characterize the impact of ...

Status

Completed

Location

Mount Sinai Hospital

Start Date

2017-07-19

Trial ID

NCT03045120

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

N/A

This CML disease registry (ASC4REAL-2) aims to gather evidence on the toler...

Status

Recruiting

Location

University of Alabama at Birmingham

Start Date

2025-12-17

Trial ID

NCT07091019

Treatments Being Tested

TKIs

Chronic Myeloid Leukemia (CML) Real-Life Database

N/A

Establish the largest possible real-life cohort collecting long-term follow...

Status

Recruiting

Location

CH Annecy Genevois

Start Date

2014-04-16

Trial ID

NCT05963061

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

PHASE3

This study was a multicenter Phase IIIb open-label, three-cohort study of a...

Status

Completed

Location

Alaska Oncology and Hematology

Start Date

2021-05-25

Trial ID

NCT04666259

Treatments Being Tested

ABL001

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

PHASE3

Phase 3, 2-arm, randomized, open label trial. Patients will be randomized t...

Status

Completed

Location

Pacific Cancer Medical Center, Inc.

Start Date

2014-07-15

Trial ID

NCT02130557

Treatments Being Tested

Bosutinib Imatinib

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.

N/A

The aim of this project is to test whether low levels of BcrAbl1, despite t...

Status

Completed

Location

CHU de Nîmes

Start Date

2021-01-01

Trial ID

NCT04965649

Treatments Being Tested

Phenotyping of total and innate CD8+T cells by flow cytometry

Previous Next